Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients requiring admission to the hospital due to a moderate and severe COVID-19 infection may differ in their ability to respond to viral infection and to eliminate viral load.
Several comorbidities and interventions like antivirotic or antiinflammatory treatment may also modify expected patients response and decrease of viral load.
In this observational study, evolution of selected inflammatory markers, indicators of severity of infection and patient characteristics will be followed and recorded in hospitalized patients with COVID-19.
In this pilot study, 30 consecutive COVID-19 patients requiring admission to the hospital due to a moderate and severe COVID-19 infection will be included into an observational study.
Following parameters will be recorded: age, sex, weight, height, comorbidities, smoking habit,spiritus and drug intake history, length of COVID-19 symptoms, clinical and laboratory parameters, the use of different COVID-19 intervention (remdesivir, convalescent plasma, monoclonal antibodies, corticosteroids, tocilizumab and other medication), used initial and maximal organ support during the stay and outcome of the stay in the hospital and 28th and 90th day, laboratory markers of severity of infection - serum and tracheal aspirate (in ventilated patients) levels of nucleocapsid antigen,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) viremia and quantity in tracheal aspirates (in ventilated patients), makers of inflammatory response (C- reactive proteins, Interleukin 6, procalcitonin, ferritin) and selected other biochemical values (blood count, D-dimers, flow cytometry).
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Prediction of severity of lung dysfunction based on initial nucleocapsid antigen serum levels | Correlation between baseline nucleocapsid serum levels and the Ordinal Scale for Clinical Improvement | Admission |
| Prediction of severity of lung dysfunction based on initial interleukin-6 serum levels | Correlation between baseline interleukin -6 serum levels and Ordinal Scale for Clinical Improvement | Admission |
| Prediction of severity of lung dysfunction based on | Correlation between baseline CRP serum levels and Ordinal Scale for Clinical Improvement | Admission |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of the dose of corticosteroids on the nucleocapsid antigen serum levels | Correlation between the dose of corticosteroids and evolution of nucleocapsid serum levels | up to 28 days |
| Effect of the remdesivir on the nucleocapsid antigen serum levels |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Hospitalized COVID-19 with moderate to severe course of COVID-19 infection.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Pavel Dostál, MD, PhD | Contact | +420602455632 | pavel.dostal@fnhk.cz | |
| Vladimir Koblizek, MD, Ph.D. | Contact | +420723448641 | vladimir.koblizek@fnhk.cz |
| Name | Affiliation | Role |
|---|---|---|
| Vladimir Palicka, MD, CSc. | University Hospital Hradec Kralove | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Hradec Kralove | Recruiting | Hradec Králové | 50005 | Czechia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D014766 | Viremia |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Comparison of the nucleocapsid antigen serum levels between patients receiving and not receiving remdesivir |
| up to 28 days |
| Effect of comorbidities on persistence of tracheal viral load assessed using tracheal aspirate semiquantitative PCR | Analysis of the effect of comorbidities on evolution of viral load assessed using tracheal aspirate semiquantitative PCR | up to 28 days |
| Effect of age on persistence of tracheal viral load assessed using tracheal aspirate semiquantitative PCR | Analysis of the effect of age on evolution of viral load assessed using tracheal aspirate semiquantitative PCR | up to 28 days |
| Effect of age on viral load assesed using nucleocapsid antigen serum levels | Analysis of the effect of age on evolution of nucleocapsid antigen serum levels | up to 28 days |
| Effect of comorbidities on viral load assessed using nucleocapsid antigen serum levels | Analysis of the effect of comorbidites on evolution of nucleocapsid antigen serum levels | up to 28 days |
| Tracheal viral load quantification using tracheal nucleocapsid antigen | Correlation between the number of cycles of amplification of real time PCR and nucleocapsid antigen tracheal aspirate levels and between the number of cycles of amplification of real time PCR and nucleocapsid antigen serum levels | up to 28 days |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D018805 | Sepsis |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |